pSivida Corp.  

(Public, NASDAQ:PSDV)   Watch this stock  
Find more results for PSDV
4.27
+0.05 (1.18%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.09 - 4.32
52 week 3.26 - 5.45
Open 4.22
Vol / Avg. 176,005.00/143,326.00
Mkt cap 125.31M
P/E 13.20
Div/yield     -
EPS 0.32
Shares 29.35M
Beta 1.43
Inst. own 25%
Dec 11, 2014
pSivida Corp Annual Shareholders Meeting
Dec 3, 2014
pSivida Corp at LD Micro Conference
Nov 7, 2014
Q1 2015 pSivida Corp Earnings Release
Nov 7, 2014
Q1 2015 pSivida Corp Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 81.27% -384.54%
Operating margin 82.15% -388.43%
EBITD margin - -364.27%
Return on average assets 248.42% -68.63%
Return on average equity 325.24% -118.06%
Employees 24 -
CDP Score - -

Address

480 Pleasant St Ste B300
WATERTOWN, MA 02472-2463
United States - Map
+1-617-9265000 (Phone)
+1-617-9265050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. As of June 30, 2011, the Company is focused on the treatment of chronic eye diseases utilizing its cored technology systems, Durasert and BioSilicon. Its product candidate ILUVIEN, for the treatment of diabetic macular edema (DME) is under review by the United States Food and Drug Administration (FDA). Its product candidate ILUVIEN, for the treatment of diabetic macular edema (DME) is under review by the United States Food and Drug Administration (FDA). The Company�s two FDA-approved products provide sustained release drug delivery to treat other back-of-the-eye diseases. An investigator-sponsored trial is ongoing for an injectable bioerodible insert delivering latanoprost designed to treat glaucoma and ocular hypertension and an investigator-sponsored Investigational New Drug opened for an injectable insert of the same design as ILUVIEN designed to treat posterior uveitis.

Officers and directors

David J. Mazzo Ph.D. Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Paul Ashton President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Leonard S. Ross Vice President - Finance, Principal Financial Officer
Age: 64
Bio & Compensation  - Reuters
Lori Freedman Vice President - Corporate Affairs, General Counsel, Company Secretary
Age: 47
Bio & Compensation  - Reuters
James J. Barry Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
Douglas Evan Godshall Independent Director
Age: 49
Bio & Compensation  - Reuters
Michael W. Rogers Independent Director
Age: 54
Bio & Compensation  - Reuters
Peter G. Savas Independent Director
Age: 64
Bio & Compensation  - Reuters